论文部分内容阅读
肺癌已成为全世界众多肿瘤中的头号杀手,其中非小细胞肺癌(non-small cell lung cancer,NSCLC)占到肺癌总数的85%左右[1]。尽管多学科综合治疗的方法,例如像分子靶标药物、抗体与化疗药物结合等介入已介入NSCLC的治疗并使其治疗效果有所改善,但反映患者预后情况的生存率指标
Lung cancer has become the number one killer in many tumors worldwide, with non-small cell lung cancer (NSCLC) accounting for about 85% of all lung cancers [1]. Although multidisciplinary approaches such as molecular target drugs, the combination of antibodies and chemotherapeutic agents have been implicated in the treatment of NSCLC and have resulted in improved outcomes, survival measures that reflect the patient’s prognosis